BackLucira Health Overview

Lucira Health Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$9.14M
36.26% YoY

As of Sep 30, 2022

Annual R&D Expenses (TTM)

$41.19M
4.93% YoY

Trailing 12 months ending Sep 30, 2022

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Lucira Health (LHDX) FAQ

Stockcircle tracks research & development for Lucira Health (LHDX), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Lucira Health's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main LHDX overview so you can move from this figure to the surrounding analysis quickly.